Analyzing Genelux (NASDAQ:GNLX) & Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics (NASDAQ:PTGX) and Genelux (NASDAQ:GNLX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Volatility and Risk

Protagonist Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Genelux has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Profitability

This table compares Protagonist Therapeutics and Genelux’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Genelux	N/A	-205.85%	-138.79%

Analyst Recommendations

This is a breakdown of recent ratings for Protagonist Therapeutics and Genelux, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0	0	16	2	3.11
Genelux	1	0	3	1	2.80

Protagonist Therapeutics presently has a consensus target price of $154.44, indicating a potential upside of 14.87%. Genelux has a consensus target price of $18.00, indicating a potential upside of 634.69%. Given Genelux’s higher possible upside, analysts clearly believe Genelux is more favorable than Protagonist Therapeutics.

Insider & Institutional Ownership

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Protagonist Therapeutics and Genelux”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02 million	189.04	-$130.15 million	$1.03	130.52
Genelux	$10,000.00	11,083.80	-$32.15 million	($0.86)	-2.85

Genelux has lower revenue, but higher earnings than Protagonist Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Protagonist Therapeutics beats Genelux on 11 of the 15 factors compared between the two stocks.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.